Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mitoxantrone liposomal - CSPC ZhongQi Pharmaceutical Technology

Next Previous
X
Search
Drug Profile

Mitoxantrone liposomal - CSPC ZhongQi Pharmaceutical Technology

Alternative Names: 2010L04017; Duoenda; Mitoxantrone hydrochloride liposome; Pegylated liposomal mitoxantrone; PLM-60

Latest Information Update: 12 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CSPC ZhongQi Pharmaceutical Technology
  • Developer CSPC ZhongQi Pharmaceutical Technology; Huizhou Municipal Central Hospital; Jinhua Central Hospital; Ningbo No. 1 Hospital; The Second Affiliated Hospital of Zhejiang University School of Medicine
  • Class Amines; Anthraquinones; Antineoplastics; Small molecules
  • Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Peripheral T-cell lymphoma
  • Phase II Breast cancer; Cutaneous T-cell lymphoma; Diffuse large B cell lymphoma; Neuromyelitis optica; Small cell lung cancer; Solid tumours
  • Phase I/II Extranodal NK-T-cell lymphoma; Immunoblastic lymphadenopathy; Non-Hodgkin's lymphoma
  • Phase I Gastric cancer; Head and neck cancer; Multiple myeloma; Oesophageal cancer; Ovarian cancer; Soft tissue sarcoma
  • Clinical Phase Unknown Liver cancer

Most Recent Events

  • 18 Jul 2024 CSPC ZhongQi Pharmaceutical Technology completes a Phase-II clinical trials in Neuromyelitis optica in China (IV) (NCT05551598)
  • 23 Feb 2024 CSPC ZhongQi Pharmaceutical Technology terminates a phase-II trial in Breast cancer (In adults, In the elderly, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in China (IV) as the sponsor had adjusted its R&D strategy (NCT04927481)
  • 21 Feb 2024 Mitoxantrone liposomal is still in phase II trials for Diffuse large B-cell lymphoma in China (NCT05875428)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top